GRI Bio Q1 net loss narrows on lower R&D expenses

GRI Bio

GRI

0.00

Overview

U.S. biotechnology firm's Q1 net loss narrowed yr/yr, driven by lower R&D expenses
Company raised $6.8 mln through At The Market facility, boosting cash to $11 mln

Outlook

Company expects existing cash to fund operations into Q2 2027
Company progressing GRI-0803 toward IND-enabling activities for autoimmune indications

Result Drivers

LOWER R&D EXPENSES - Co said Q1 research and development expenses fell due to completion of Phase 2a trial of GRI-0621 in 2025

Company press release: ID:nGNX4CZHtV

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 Net Income		-$2 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for GRI Bio Inc is $160.00, about 6,979.6% above its May 13 closing price of $2.26

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.